There is no such thing as a biocompatible material.

This Leading Opinion Paper discusses a very important matter concerning the use of a single word in biomaterials science. This might be considered as being solely concerned with semantics, but it has implications for the scientific rationale for biomaterials selection and the understanding of their performance. That word is the adjective 'biocompatible', which is often used to characterize a material property. It is argued here that biocompatibility is a perfectly acceptable term, but that it subsumes a variety of mechanisms of interaction between biomaterials and tissues or tissue components and can only be considered in the context of the characteristics of both the material and the biological host within which it placed. De facto it is a property of a system and not of a material. It follows that there can be no such thing as a biocompatible material. It is further argued that in those situations where it is considered important, or necessary, to use a descriptor of biocompatibility, as in a scientific paper, a regulatory submission or in a legal argument, the phrase 'intrinsically biocompatible system' would be the most appropriate. The rationale for this linguistic restraint is that far too often it has been assumed that some materials are 'universally biocompatible' on the basis of acceptable clinical performance in one situation, only for entirely unacceptable performance to ensue in quite different clinical circumstances.

[1]  C. Pui,et al.  Management of occlusion and thrombosis associated with long-term indwelling central venous catheters , 2009, The Lancet.

[2]  T. Krieg,et al.  Fibroblast-matrix interactions in wound healing and fibrosis. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[3]  David Williams,et al.  Essential Biomaterials Science , 2014 .

[4]  David F Williams,et al.  The biomaterials conundrum in tissue engineering. , 2014, Tissue engineering. Part A.

[5]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[6]  R. Tannenbaum,et al.  Use of polyelectrolyte thin films to modulate osteoblast response to microstructured titanium surfaces. , 2012, Biomaterials.

[7]  Wenjie Zhang,et al.  Maintenance of phenotype and function of cryopreserved bone-derived cells. , 2011, Biomaterials.

[8]  Takahiro Nomoto,et al.  Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors. , 2014, Biomaterials.

[9]  S. Doak,et al.  NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. , 2009, Biomaterials.

[10]  Pieter van Dokkum,et al.  The nature of , 2006 .

[11]  S. M. Sims,et al.  The differential regulation of osteoblast and osteoclast activity by surface topography of hydroxyapatite coatings. , 2013, Biomaterials.

[12]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[13]  J. Charnley TISSUE REACTIONS TO POLYTETRAFLUORETHYLENE , 1963 .

[14]  R. Duncan The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[15]  Donnie F. Williams Concepts in biocompatibility: new biomaterials, new paradigms and new testing regimes , 2012 .

[16]  Cameron J Wilson,et al.  Mediation of biomaterial-cell interactions by adsorbed proteins: a review. , 2005, Tissue engineering.

[17]  J. Boutrand Biocompatibility and performance of medical devices , 2012 .

[18]  James M. Anderson,et al.  Foreign body reaction to biomaterials. , 2008, Seminars in immunology.

[19]  D. Mooney,et al.  Growth factor delivery-based tissue engineering: general approaches and a review of recent developments , 2011, Journal of The Royal Society Interface.

[20]  Meredith A Mintzer,et al.  Nonviral vectors for gene delivery. , 2009, Chemical reviews.

[21]  Jianxiang Zhang,et al.  The role of surface chemistry in determining in vivo biodistribution and toxicity of CdSe/ZnS core-shell quantum dots. , 2013, Biomaterials.

[22]  F. Schoen Mechanisms of function and disease of natural and replacement heart valves. , 2012, Annual review of pathology.

[23]  J. Simon,et al.  Immune responses to implants - a review of the implications for the design of immunomodulatory biomaterials. , 2011, Biomaterials.

[24]  Laura E Niklason,et al.  Alveolar epithelial differentiation of human induced pluripotent stem cells in a rotating bioreactor. , 2014, Biomaterials.

[25]  Melissa L Knothe Tate,et al.  Modulation of stem cell shape and fate B: mechanical modulation of cell shape and gene expression. , 2008, Tissue engineering. Part A.

[26]  David F. Williams On the nature of biomaterials. , 2009, Biomaterials.

[27]  R. Mitchell,et al.  Graft vascular disease: immune response meets the vessel wall. , 2009, Annual review of pathology.

[28]  Fei Wang,et al.  Material Properties of the Cell Dictate Stress-induced Spreading and Differentiation in Embryonic Stem Cells Growing Evidence Suggests That Physical Microenvironments and Mechanical Stresses, in Addition to Soluble Factors, Help Direct Mesenchymal-stem-cell Fate. However, Biological Responses to a L , 2022 .

[29]  N. Jacobsen,et al.  Role of oxidative damage in toxicity of particulates , 2010, Free radical research.

[30]  David F. Williams On the mechanisms of biocompatibility. , 2008, Biomaterials.

[31]  Ralph Müller,et al.  Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. , 2013, Biomaterials.